Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabazitaxel injection - Beihai Biotech

Next Previous
Drug Profile

Cabazitaxel injection - Beihai Biotech

Alternative Names: BH-002; BH002 injection

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beihai Biotech
  • Class Amines; Antineoplastics; Benzene derivatives; Esters; Small molecules; Taxanes
  • Mechanism of Action Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for phase-I development in Prostate-cancer(Late-stage disease) in China (Parenteral, Injection)
  • 21 Jun 2022 Cabazitaxel injection - Beihai Biotech is available for licensing as of 17 Jun 2022. http://www.bayhibiotech.com/page115
  • 02 Jan 2022 Phase-I clinical trials in Prostate cancer (Late-stage disease) in China (unspecified route) before January 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top